The German Medicines Commission (AMK), which consists of 21 experts from pharmacy, medicine, science, and practice, has announced new appointments to its board. Professor Dr. Martin Schulz will continue to serve as the chairperson of the AMK. The commission includes specialists in various domains of pharmacy and drug safety, including pharmacology, toxicology, cardiology, and intensive care medicine. Notably, Dr. Armin Hoffmann, the president of the Federal Chamber of Pharmacists, is also a member of the AMK. The newly appointed members are Professor Dr. Burkhard Kleuser and Professor Dr. Anne Seidlitz from the University of Berlin, along with Professor Dr. Martina Hahn from Varisano Kliniken Frankfurt-Main-Taunus. Their inclusion comes after the departure of Professor Dr. Rolf Daniels, Professor Dietmar Schrenk, and Professor Dr. Christoph Stein, who exited the AMK at the end of 2024. The AMK plays a vital role in the German healthcare system, primarily overseeing drug safety and risk management. In 2024 alone, the commission received over 10,000 reports from pharmacies regarding potential drug risks, as highlighted by ABDA President Thomas Preis. The AMK is responsible for timely communication regarding product recalls, side effects, and quality issues. As a part of the ABDA, the AMK enhances medication safety and provides pharmacists with up-to-date professional information and statements, significantly contributing to the protection of patients across the nation. The commission, in conjunction with its office in Berlin, manages the tasks associated with drug risk mitigation as defined primarily in the Medicines Act. Pharmacists are mandated by the professional regulations of the pharmacy chambers to report any drug-related risks to the AMK. Furthermore, the AMK's office ensures national communication with authorities, pharmaceutical companies, and pharmacies. This year marks the 50th anniversary of the AMK, which has been instrumental in advocating for drug safety and effective communication within the pharmaceutical community. The commission's ongoing efforts underscore its commitment to maintaining high standards of patient care and safety in the German healthcare system.